OUR SOLUTION
Beyond DNA Sequencing
SEngine Precision Medicine empowers patients and oncologists with more informed treatment options. SEngine's high-throughput technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The results decode the most effective and least toxic treatment options that DNA sequencing alone cannot reveal. The proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs.
AVAILABLE NOW
Serving Patients, Research Partners and Pharmaceuticals
The PARIS® Test is the antidote for today's failing standard of care. DNA sequencing alone predicts effective treatment an estimated 15% of the time. The PARIS® Test delivers effective treatment options for solid tumors up to 80% of the time, based on recent testing. As a CLIA-certified lab, SEngine is the only lab which provides actionable reports directly to oncologists today.
Patient Impact
SEngine Precision Medicine is having an impact on patient’s lives. Hear testimonials about the PARIS Test from Nobel laureate scientist, Dr. Lee Hartwell, and Ingrid Kolstoe, patient and survivor.
As Seen IN
